What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?
- PMID: 36924121
- PMCID: PMC10121283
- DOI: 10.3350/cmh.2023.0080
What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?
Keywords: Diagnosis; Hepatocellular carcinoma; Practice guideline; Surveillance; Treatment.
Conflict of interest statement
Dr. Kim YJ reports receiving research grants from BTG, Boston Scientific, AstraZeneca, Gilead Sciences, Samjin, BL&H, and Bayer, and lecture fees from Roche, Abbvie, Eisai, Boston Scientific, BMS, BTG, Bayer, MSD, Gilead, Novo Nordisk, Green Cross Cell, Boehringer Ingelheim, and Gilead.
Comment on
-
Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective.Clin Mol Hepatol. 2023 Apr;29(2):197-205. doi: 10.3350/cmh.2022.0404. Epub 2023 Jan 5. Clin Mol Hepatol. 2023. PMID: 36603575 Free PMC article. Review.
References
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–249. - PubMed
-
- Korean Liver Cancer Study Group and National Cancer Center [Practice guidelines for management of hepatocellular carcinoma 2009] Korean J Hepatol. 2009;15:391–423. Korean. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
